Valeant Pharmaceuticals on Friday increased the list price of three products, Atropine Sulfate Ophthalmic Ointment, PrednisoLONE Sodium Phosphate Ophthalmic Solution and Neomycin-Polymyxin-Gramicidin Ophthalmic Solutions, each by 9.9%, Wells Fargo analyst David Maris tells investors in a research note, citing data from Medi-Span CDI. All three products represent just $1.2M in combined sales last quarter, Maris points out. He believes the price raises, while insignificant, could be a sign that Valeant's guidance for the second half of 2016 "is tight enough" that raising price on marginal products is what the company "feels is necessary." Further, the 9.9% increases "seems very odd" and may be an attempt to stay under the radar of managed care plans and states looking out for double-digit price increases, Maris argues. He believes Valeant will be challenged to make its guidance for 2016 and keeps an Underweight rating on the shares with a $17-$22 price target range. The stock on Friday closed down 9c to $27.28.